Table 4. Putative transcriptional regulators and chemicals associated with expression profiles in TKI-resistant sublines.
| Gene set | Condition | Gene set annotation | Gene size | P-value |
|---|---|---|---|---|
| Regulatory motif gene set | Resistance-up | V$ICSBP_Q6 | 122 | 5.2E−07 |
| STTTCRNTTT_V$IRF_Q6 | 99 | 1.8E−05 | ||
| V$EVI1_02 | 67 | 3.0E−05 | ||
| YAATNRNNNYNATT_UNKNOWN | 38 | 6.6E−05 | ||
| TTANWNANTGGM_UNKNOWN | 24 | 7.7E−05 | ||
| V$OCT1_06 | 125 | 0.0001 | ||
| V$IRF1_01 | 119 | 0.0002 | ||
| V$TCF11_01 | 109 | 0.0003 | ||
| V$WHN_B | 128 | 0.0005 | ||
| V$CDX2_Q5 | 111 | 0.0005 | ||
| V$CART1_01 | 95 | 0.0006 | ||
| Resistance-down | V$ETF_Q6 | 61 | 2.1E−06 | |
| V$E2F_Q2 | 96 | 7.6E−05 | ||
| Connectivity map gene set | Resistance-up | Tamoxifen (1.0E−06M)_Down | 49 | 4.8E−09 |
| Rosiglitazone_Down | 41 | 4.4E−08 | ||
| Sodium phenylbutyrate (1.0E−03M, HL60, medium)_Up | 57 | 2.7E−07 | ||
| Cobalt chloride (1.0E−04M)_Up | 44 | 2.3E−06 | ||
| Rofecoxib (PC3)_Up | 32 | 4.1E−05 | ||
| Butein (PC3)_Down | 64 | 5.5E−05 | ||
| Troglitazone_Down | 41 | 5.8E−05 | ||
| Pyrvinium (1.3E−06M)_Up | 50 | 9.3E−05 | ||
| Gefitinib (HL60)_Up | 42 | 0.0001 | ||
| Blebbistatin (1.7E−05M)_Up | 39 | 0.0002 | ||
| Sodium phenylbutyrate (1.0E−03M, PC3, medium)_Up | 33 | 0.0002 | ||
| SC-58125 (HL60)_Up | 47 | 0.0003 | ||
| Rofecoxib_Up | 38 | 0.0004 | ||
| Monorden (1.0E−07M, PC3)_Up | 63 | 0.0008 | ||
| Resistance-down | Imatinib (PC3)_Up | 48 | 0.0002 | |
| Pirinixic acid (1.0E−04M, SKMEL5)_Up | 58 | 0.0003 |
Abbreviation: TKI, tyrosine kinase inhibitors.